NEW YORK (GenomeWeb News) – UK genotoxicity assay firm Gentronix and French personalized medicine company BioQuanta SA recently announced a deal for the commercialization of services based on BioQuanta's Mitoxis functional metabolomics platform.
Under the agreement, Gentronix will distribute Mitoxis services worldwide, providing researchers access to more than 70 discrete assays covering functional metabolism necessary for the early detection of toxicity liabilities, including electron-transport chain, oxidative stress, cellular energy status, inflammation, and cell death.
Financial terms were not disclosed.
Mitoxis is an in vitro platform "based on a global analysis of the effects of a compound on cellular metabolism," according to BioQuanta's website. It said that the platform allows for the simultaneous analysis of more than 30 parameters on the same reduced sample volume of less than 5 microliters with limited or no sample preparation.
The coefficient of variation is less than 4 percent, BioQuanta added, reducing inter-sample variability and "leading to increased confidence in the results and a better understanding of inter-dependencies between parameters."
Gentronix is based in Manchester, UK and helps firms develop drugs and chemicals by reducing the rates of attrition due to toxicity. BioQuanta SA, based in Paris and a subsidiary of BioQuanta, provides services to firms developing new drugs and diagnostics for stratifying patients.
In addition to Mitoxis, BioQuanta offers services based on its MultiDip platform for predicting and understanding the toxicity and ADME parameters of molecules.